Showing results (51-60 of 56) with videos related to
Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 56 results.
European Journal of Nuclear Medicine and Molecular Imaging|September 3, 2020
Long-term outcome of "Sandwich" chemo-PRRT: a novel treatment strategy for metastatic neuroendocrine tumors with both FDG- and SSTR-avid aggressive diseaseRahul V Parghane, Vikas Ostwal, Anant Ramaswamy, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 27, 2021
Surgical Feasibility, Determinants, and Overall Efficacy of Neoadjuvant <sup>177</sup>Lu-DOTATATE PRRT for Locally Advanced Unresectable Gastroenteropancreatic Neuroendocrine TumorsRahul V Parghane, Manish Bhandare, Vikram Chaudhari, et al.Nuclear Medicine Communications|July 8, 2024
Internal dosimetry and biodistribution of indigenously prepared 177 Lu-DOTA-rituximab in lymphoma and other hematological malignancies treated with rituximabYeshwanth Edamadaka, Rahul V Parghane, Sudeep Sahu, et al.Clinical Nuclear Medicine|February 13, 2024
Clinical Internal Dosimetry and Biodistribution of 177 Lu-DOTA-Trastuzumab in HER2-Positive Metastatic and Locally Advanced Breast CarcinomaYoga S Narwadkar, Rahul V Parghane, Sudeep Sahu, et al.American Journal of Nuclear Medicine and Molecular Imaging|September 15, 2020
One decade of 'Bench-to-Bedside' peptide receptor radionuclide therapy with indigenous [<sup>177</sup>Lu]Lu-DOTATATE obtained through 'Direct' neutron activation route: lessons learnt including practice evolution in an Indian settingSandip Basu, Sudipta Chakraborty, Rahul V Parghane, et al.BMC Cancer|October 29, 2025
PReCedeNT trial: Phase III randomized-controlled trial of Lutetium - 177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) plus Chemotherapy versus PRRT alone in FDG-avid, Well-differentiated Gastroenteropancreatic neuroendocrine tumors (GEP-NETs)Ameya D Puranik, Indraja D Dev, Sushil Yadav, et al.Pageof 6